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Abstract: In the current paper we studied the interest of a series of 3-
arylcoumarin derivatives as xanthine oxidase inhibitors. For the best 
compound of the series, the 4’-methoxyphenyl-6-nitrocoumarin, it was 
determined the IC50 value and the type of inhibition. This work is a preliminary 
screening for further design and synthetize new non-purinergic derivatives as 
potential compounds involved in the inflammatory suppression, specially 
related to the gout. 
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1. Introduction 
Xanthine oxidase (XO, EC 1.2.3.2) is a form of molybdoflavin protein that 
plays an important role at the end of the catabolic sequence of the purine 
nucleotide metabolism in humans and a few other uricotelic species.1 It firstly 
catalyzes of hypoxanthine to xanthine, and then transforms it into uric acid, 
which is excreted in the urine. Overproduction or under excretion of uric acid 
in humans could lead to hyperuricemia and gout, which is caused by 
crystallization and deposition of uric acid in joints and surrounding tissue.2 
Gout is a metabolic disorder associated with abnormal amounts of uric acid in 
the body, which causes inflammation, gouty arthritis, and uric acid 
nephrolithiasis. 
Recent studies have indicated that asymptomatic hyperuricemia is associated 
with or may have a casual relationship with cardiovascular disease. 3 
Allopurinol (1H-pyrazol[3,4-d]pyrimidin-4-ol, Figure 1) is a substrate and 
specific potent inhibitor for XO, and has been used for gout treatment for a 
number of years.4 Several studies have indicated that allopurinol may induce 
hypersensitivity syndrome an Stevens-Johnson syndrome in patients.5 , 6 , 7 
More recently, febuxostat (2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-
thiazole-5-carboxylic acid, Figure 1), a new non-purine XO inhibitor, has been 
approved for management of gout in the European Union and USA.4,8 Many 
side effects of febuxostat have been reported.9 
 
 
Figure 1. Chemical structure of allopurinol (reference compound) and 
febuxostat. 
 
In this study, we intended to develop XO inhibitors with potent activity and low 
toxicity, using compounds with a chemical structure distinct from allopurinol 
and febuxostat. Therefore, XO inhibitory activity was evaluated and compared 
with allopurinol. 
 
2. Results and discussion 
Based on previous findings in the area, and in our experience with substituted 
3-arylcoumarins, in the present work we proposed the synthesis (Scheme 1) 














arylcoumarins.10 ,11  With the aim of finding the structural features for the 
biological activity, we decided to explore the importance of the nature and 
position of small groups (methoxy, nitro and hydroxyl substituents) into both 
coumarin nucleus and 3-aryl ring (Scheme 1). 
 
Scheme 1. Synthesis of 3-arylcoumarin derivatives. Reagents and conditions: 
a) sodium carbonate (2.0 equiv), palladium complex (0.5 mol %), DMF/H2O 
(1:1), 110 oC, 120–180 min. b) NaH (1.0 equiv), acetic anhydride, r.t., 3 h. 
 
The derivatives 1-3 were efficiently synthesized by a direct cross-coupling 
reaction, in presence of sodium carbonate, N,N’-bis(salicylidene)-
ethylenediamino-palladium (salen-Pd), Na2CO3 in DMF/H2O (1:1), at 110 oC, 
for 120–180 min. The reaction mixture was purified by flash chromatography, 
using hexane/ethyl acetate as eluent in a proportion of 9:1. Starting from the 
3-chlorocoumarin and the respectively substituted arylboronic acids, we 
obtained three derivates in good yields (56–64%). 
The derivatives 4-6 were efficiently synthesized by a condensation reaction in 
a dry Schlenk tube, in presence of sodium hydride and with acetic anhydride 
as solvent, at room temperature for three hours. The reaction mixture was 
purified by flash chromatography, using hexane/ethyl acetate as eluent in a 
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salicylaldehyde and the respectively substituted arylacetic acids, we obtained 
three derivates in good yields (60–75%). 
 
Table 1. XO inhibition for compounds 1-6.  
Compounds 





1 22.5 - - 
2 40.38 - - 
3 14.5 - - 
4 19.2 - - 
5 85 9.0 Uncompetitive 
6 76.6 - - 
Allopurinol12 - 0.1 Competitive 
 
In general, the studied 3-arylcoumarins presented no significant inhibitory 
activity against XO (Table 1). Compound 5 (4’-methoxyphenyl-6-
nitrocoumarin) proved to be the best candidate of the series. Therefore, the 
IC50 of this compound was calculated (9.0 µM) and the compound proved to 
be 90 times less active than allopurinol, used as reference compound. In 
addition, the type of inhibition was also determined (Figure 2). This 
compound is an uncompetitive inhibitor of XO, in contradiction to the 
reference compound.  
 
 
Figure 2. Lineweaver-Burk plots for inhibition of compound 5 on XO. 
Concentrations of compound 5 were 0 (●), 2.5 (○), 5.0 (□) and 7.5 (■) µM. 
 
3. Conclusion 
Compound 5 proved to be the best XO inhibitor of the studied series. It is an 
uncompetitive inhibitor that could be the inspiration for the design of further 
non-purinergic XO inhibitors.  
 
4. Experimental methodologies 
 
4.1. Synthesis 
General procedure for the preparation of 3-arylcoumarins 1-3. To a 20 mL two 
neck round bottomed flask was added a solution of 3-chlorocoumarin (0.83 
mmol), arylboronic acid (1.04 mmol), Na2CO3 (1.66 mmol), and Pd-salen 
complex (0.5 mol %) in DMF/H2O (1:1). The reaction mixture was heated at 
110 oC for 120–180 min. The reaction was monitored by chromatography. 
After the completion of the reaction, the mixture was extracted with ethyl 
acetate (3 x 20 mL). The organic extracts were dried over anhydrous sodium 
sulphate, filtrated, and the solvent was evaporated under vacuum. The 
obtained crude product was purified by column chromatography (hexane/ethyl 












General procedure for the preparation of 3-arylcoumarins 4-6. In a 20 mL dry 
Schlenk tube, to a solution of the conveniently substituted salicylaldehyde 
(2.46 mmol) and the arylacetic acid (2.46 mmol), in acetic anhydride (6 mL), 
NaH (2.46 mmol) was added in small portions, and the reaction mixture was 
stirred for 3 hours, at room temperature. The obtained crude was filtered and 
washed with diethyl ether. The solid was then purified by flash 
chromatography (hexane/ethyl acetate 9:1) to give the desired coumarins 4-6. 
 
4.2. Biological assays  
The biological assays were carried out following the protocol described below. 
0.1 M of phosphate buffer solution (pH 7.5), an aqueous solution of XO (0.5 
U/mL, Sigma Chemical Co) and DMSO with or without the compound. Then, a 
0.82 mM of xanthine solution was added and the activity of the XO was 
determined spectrophotometrically (Varian Cary 50) by measuring the 
formation of uric acid at 295 nm. The percent of XO activity inhibition was 
calculated as: inhibition (%) = (A – B) / A x 100, where A represents the 
difference in the absorbance of control sample between 0.5 and 1.0 min, and 
B represents the difference in absorbance of the test sample between 0.5 and 
1.0 min. The IC50 value, a concentration giving 50 % inhibition of XO activity, 
was determinate by interpolation of dose-response curves. Allopurinol was 
used as a reference XO inhibitor. 
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